AI Article Synopsis
- Traditionally, APOE genetic testing wasn't part of standard practices for diagnosing and managing Alzheimer's disease.
- Recent studies emphasize its significance, particularly in evaluating the safety of anti-amyloid-β treatments like lecanemab, which now recommend such testing.
- However, implementing this testing in clinical settings raises various clinical, ethical, legal, and economic challenges that need thorough discussion, especially in Japan.
Article Abstract
Conventionally, APOE genetic testing has not been recommended as a component of the standard diagnostic and management practices for Alzheimer's disease. However, recent research highlights the importance of this test, particularly for assessment of the safety profile of anti-amyloid-β therapies. Therefore, the current United States guidelines for the administration of lecanemab explicitly advise APOE genetic testing. However, integration of this testing into clinical practice is associated with many clinical, ethical, legal, and economic challenges. It is important to initiate comprehensive discussions to address these multifaceted issues in Japan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.11477/mf.1416202728 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!